The Role of C1q Tumor Necrosis Factor-related Protein 6 in Breast Cancer
NCT ID: NCT04611308
Last Updated: 2020-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
102 participants
OBSERVATIONAL
2020-11-01
2022-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The etiology of breast cancer is multifactorial in which multiple epigenetic and genetic variations affect its incidence and prognosis . Although diagnostic methods and therapeutic strategies for breast cancer have been improved in past decades, long-term survival of breast cancer patients still remains poor due to high proliferation, metastasis and post-surgical recurrence rate.
Therefore, it is critical to develop more effective screening methods that can detect BC at an early stage and novel therapeutic targets for better treatment. This may be achieved by understanding the molecular mechanisms underlying the initiation and progression of this malignancy.
Complement C1q tumor necrosis factor-related protein (CTRPs) are a protein family of adiponectin paralogs which contains fifteen members, CTRP1- CTRP15. This super family are involved in several biological processes, including metabolism, immunity, inflammation, apoptosis and cell differentiation (15, 16). Accumulating evidence correlates CTRP family members with carcinogenesis and signaling pathways associated with cancer development, progression and metastasis.
C1q tumor necrosis factor-related protein 6 (CTRP6) or (C1qTNF6) is a member of CTRPs family. It contains four domains including signal peptide, short N-terminal variable region, collagen domain and C-terminal C1q domain. It is expressed mainly in placenta, heart, uterus and adipose tissue.
CTRP6 is involved in multiple physiological processes, such as regulating cell proliferation and differentiation. It also mediates fatty acid oxidation, adipogenesis and insulin sensitivity, attenuates cell fibrosis and displays anti-inflammatory properties.
Although recent studies have revealed that adiponectin has an inhibitory role in carcinogenesis, the role of CTRP6 in carcinogenesis remains unclear. CTRP6 was initially found to be overexpressed and possibly contributes to tumor angiogenesis in many hepatocellular carcinomas. Moreover, recent research indicates that CTRP6 is correlated with gastric cancer progression by mediating proliferation, migration and apoptosis, which reveals a similar pattern in lung adenocarcinoma.
However, tumor suppressor functions of CTRP6 were also successively reported. CTRP6 was found to have inhibitory effect on the proliferation and migration of ovarian cancer cells. Moreover, CTRP6 significantly suppressed the growth and invasion activity of the oral squamous cell carcinoma cells.
The role CTRP6 plays in breast cancer is yet unknown. The present study will investigate the level of CTRP6 in BC specimens. Furthermore, the pathological functions of CTRP6 in BC, including cell growth, proliferation, migration, and effect on inflammation and angiogenesis will be studied in breast cancer cells.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cases
C1q tumor necrosis factor-related protein 6 levels
C1q tumor necrosis factor-related protein 6 is a tumor marker
controls
C1q tumor necrosis factor-related protein 6 levels
C1q tumor necrosis factor-related protein 6 is a tumor marker
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
C1q tumor necrosis factor-related protein 6 levels
C1q tumor necrosis factor-related protein 6 is a tumor marker
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly diagnosed patients with histopathological confirmation of the diagnosis of breast cancer at any stage.
Exclusion Criteria
* Patients with more than one cancer.
* Patients treated with chemotherapy or radiotherapy before initial samples collection.
* Pregnant women.
* Patients with unqualified or insufficient data.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Samia Farouk Hamed Ahmed
Samia Farouk Hamed Ahmed
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTRP6 in Breast Cancer
Identifier Type: -
Identifier Source: org_study_id